Work

Activity of Tigecycline (GAR-936), a Novel Glycylcycline, against Enterococci in the Mouse Peritonitis Model

Year: 2003

Type: article

Abstract: A novel glycylcycline agent, tigecycline (GAR-936), was evaluated in vivo in the mouse model of peritonitis against three Enterococcus faecalis and four Enterococcus faecium isolates with different susceptibilities to vancomycin and tetracyclines, all of which were inhibited by </=0.125 micro g of tigecycline/ml. Using a single subcutaneous dose, tigecycline displayed a protective effect (50% protective dose, </=5.7 mg/kg of body weight) against all strains tested, including two with Tn925 (from the Tn916 family), which contains the Tet(M) tetracycline resistance determinant, as well as VanA and VanB strains. As expected, tetracycline and minocycline were ineffective against the isolates carrying Tn925.

Source: Antimicrobial Agents and Chemotherapy

DOI: 10.1128/aac.47.2.529-532.2003

Authors: Esteban C. Nannini, Suresh R. Pai, Kavindra V. Singh, Barbara E. Murray

Language: English

Topic: Antibiotic Resistance in Bacteria

Subfield: Molecular Medicine

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: Centers for Disease Control and Prevention

OpenAlex ID: W2120706333

FWCI: 3.048

Cites: 22

Cited by: 37

Related to: 10